ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

General Practice

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,989Medicare Part D Prescriptions Filled, Including Refills
$399K Total Retail Price of All Prescriptions
354 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
LEVOTHYROXINE SODIUM 431 414
FUROSEMIDE 350 336
SIMVASTATIN 344 330
LISINOPRIL 330 299
OMEPRAZOLE 251 232
KLOR-CON 10 244 229
METFORMIN HCL 210 180
WARFARIN SODIUM 169 169
POTASSIUM CHLORIDE 164 158
SERTRALINE HCL 152 148
AMLODIPINE BESYLATE 148 148
FAMOTIDINE 147 147
HYDROCHLOROTHIAZIDE 146 142
CARVEDILOL 136 131
DIGOXIN 129 129
METOPROLOL SUCCINATE 127 127
LOVASTATIN 127 126
TAMSULOSIN HCL 121 107
ATORVASTATIN CALCIUM 116 85
ATENOLOL 110 108
CITALOPRAM HBR 106 100
POLYETHYLENE GLYCOL 3350 99 97
DOXAZOSIN MESYLATE 92 92
TRAMADOL HCL 92 62
PREDNISONE 89 81
HYDROCODONE-ACETAMINOPHEN 86 77 S3
SYNTHROID 84 84
CEPHALEXIN 81 80
METOPROLOL TARTRATE 81 81
ZOLPIDEM TARTRATE 80 75
NEXIUM 79 66
SPIRONOLACTONE 72 72
CARBIDOPA-LEVODOPA 72 70
DONEPEZIL HCL 71 71
LISINOPRIL-HYDROCHLOROTHIAZIDE 64 54
SULFAMETHOXAZOLE-TRIMETHOPRIM 62 62
DICLOFENAC SODIUM 60 47
GABAPENTIN 60 53
DIOVAN 59 56
BUMETANIDE 59 58
QUETIAPINE FUMARATE 58 56
ALENDRONATE SODIUM 54 54
GLYBURIDE 53 49 R
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 9, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.